UBS Group AG Purchases 318,787 Shares of Elanco Animal Health (NYSE:ELAN)

UBS Group AG increased its position in shares of Elanco Animal Health (NYSE:ELAN) by 78.2% during the 2nd quarter, Holdings Channel reports. The fund owned 726,362 shares of the company’s stock after buying an additional 318,787 shares during the quarter. UBS Group AG’s holdings in Elanco Animal Health were worth $24,552,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in Elanco Animal Health during the 2nd quarter worth approximately $32,000. Capital Investment Advisory Services LLC boosted its stake in Elanco Animal Health by 1,501.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock worth $36,000 after acquiring an additional 1,051 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in Elanco Animal Health by 376.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after acquiring an additional 1,130 shares during the last quarter. Zions Bancorporation N.A. boosted its stake in Elanco Animal Health by 68.1% during the 2nd quarter. Zions Bancorporation N.A. now owns 1,750 shares of the company’s stock worth $59,000 after acquiring an additional 709 shares during the last quarter. Finally, Citizens Financial Group Inc RI boosted its stake in Elanco Animal Health by 26.5% during the 2nd quarter. Citizens Financial Group Inc RI now owns 1,875 shares of the company’s stock worth $63,000 after acquiring an additional 393 shares during the last quarter.

In other news, insider Todd S. Young bought 10,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $26.57 per share, for a total transaction of $265,700.00. Following the completion of the acquisition, the insider now owns 28,883 shares in the company, valued at $767,421.31. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Dawei Li bought 1,384,717 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $1.05 per share, for a total transaction of $1,453,952.85. Insiders bought 1,497,497 shares of company stock worth $4,457,115 over the last quarter. 0.04% of the stock is owned by corporate insiders.

Several research firms recently weighed in on ELAN. ValuEngine raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday. UBS Group raised shares of Elanco Animal Health from a “sell” rating to a “neutral” rating and cut their price target for the company from $31.00 to $30.00 in a research note on Thursday, August 15th. Zacks Investment Research lowered shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Friday, September 6th. Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research note on Monday, September 9th. They issued a “positive” rating on the stock. They noted that the move was a valuation call. Finally, Barclays initiated coverage on shares of Elanco Animal Health in a research note on Monday, September 23rd. They issued an “overweight” rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $33.98.

ELAN traded up $0.75 during trading on Thursday, reaching $26.70. The company had a trading volume of 98,556 shares, compared to its average volume of 4,790,115. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.07 and a quick ratio of 1.71. Elanco Animal Health has a 12 month low of $25.51 and a 12 month high of $35.46. The business’s fifty day moving average price is $27.32 and its 200 day moving average price is $31.28. The company has a market cap of $9.49 billion and a P/E ratio of 22.63.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.02. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. The company had revenue of $781.60 million for the quarter, compared to the consensus estimate of $781.49 million. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. As a group, sell-side analysts predict that Elanco Animal Health will post 1.08 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Article: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.